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ABSTRACT 
 Imaging plays an important role in the detection, diagnosis, staging, response assessment, 
and surveillance of malignant pleural mesothelioma.  The etiology, biology, and growth pattern 
of mesothelioma present unique challenges for each modality used to capture various aspects of 
this disease.  Clinical implementation of imaging techniques and information derived from 
images continue to evolve based on active research in this field worldwide.  This paper 
summarizes the imaging-based research presented orally at the 2016 International Conference of 
the International Mesothelioma Interest Group (iMig) in Birmingham, United Kingdom, held 
May 1-4, 2016.  Presented topics included intraoperative near-infrared imaging of mesothelioma 
to aid the assessment of resection completeness, an evaluation of tumor enhancement 
improvement with increased time delay between contrast injection and image acquisition in 
standard clinical magnetic resonance imaging (MRI) scans, the potential of early contrast 
enhancement analysis to provide MRI with a role in mesothelioma detection, the differentiation 
of short- and long-term survivors based on MRI tumor volume and histogram analysis, the 
response-assessment potential of hemodynamic parameters derived from dynamic contrast-
enhanced computed tomography (DCE-CT) scans, the correlation of CT-based tumor volume 
with the post-surgical tumor specimen weight, and consideration of the need to update the 
mesothelioma tumor response assessment paradigm. 
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1. Introduction 
 The International Mesothelioma Interest Group (iMig) (www.imig.org) holds a biennial 
conference to which advances in imaging research and clinical applications of imaging 
technologies have made key contributions [1-4].  Researchers, clinicians, and radiologists 
continue to seek ways to expand the capabilities of imaging with the intent of extracting as much 
anatomic or physiologic information from mesothelioma patients as possible and to apply 
imaging technologies most appropriately to patient management in both routine practice and 
clinical trials research.  This paper summarizes research presented in the “Imaging and Endpoint 
Evaluation” session of the 2016 International Conference of the International Mesothelioma 
Interest Group in Birmingham, United Kingdom, May 2016. 
 Key clinical goals of imaging in malignant pleural mesothelioma are early detection of 
disease, optimising sensitivity and specificity for anatomic involvement of unresectable planes to 
identify patients who are suitable for surgical resection, improving prognostication, and 
assessing response to treatment as a surrogate for therapeutic benefit.  The imaging reported in 
the context of mesothelioma typically includes computed tomography (CT), magnetic resonance 
imaging (MRI), and positron emission tomography (PET) scans; these scans may be acquired 
during initial tumor diagnosis and staging, treatment response assessment, or patient 
surveillance, depending on the clinical question being asked.  Optical imaging, using 
electromagnetic radiation in (or near) the visible light region of the spectrum, has been an active 
area of research for a wide range of medical applications [5] and is now being applied in the 
intraoperative setting for mesothelioma.  Initial results indicate the potential for optical imaging 
to aid surgeons in their attempt to achieve a macroscopic complete resection. 
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 The advancement of MRI for the benefit of mesothelioma patients continues to attract the 
attention of clinical investigators.  Tumor contrast enhancement in MRI has long provided 
information about tumor vascularity, but new evidence suggests that the clinically conventional 
time delay between contrast injection and initiation of image acquisition might be too short for 
optimal assessment of mesothelioma.  Juxtaposed with the potential need for longer delay times 
in standard MRI is a perfusion-based MRI technique designed to capture early contrast-
enhancement features of the pleura that might be characteristic of early-stage mesothelioma, thus 
enabling a possible tumor detection role for MRI in this setting.  MRI also offers functional 
imaging capabilities through diffusion-weighted imaging (DWI), which is being used to compute 
tumor volume and parameters of the tumor pixel-value histogram in an attempt to differentiate 
between patients with long- and short-term overall survival. 
 Imaging of tumor perfusion with computed tomography (CT) has become routine for 
some tumors; however, dynamic contrast-enhanced computed tomography (DCE-CT) has only 
recently been applied to mesothelioma [3].  Investigation of this imaging technique continues 
with the computation of hemodynamic parameters designed to capture physiologic changes in 
the tumor that are not necessarily reflected in tumor thickness change.  The ultimate goal of this 
approach is an earlier assessment of pharmacodynamic endpoints and tumor response. 
 The potential role of image-based mesothelioma tumor volume in staging [6], the impact 
of volume on tumor response assessment [7-10], the correlation between tumor volume and 
patient survival [7-9,11], and the computerized extraction of mesothelioma tumor volume from 
CT scans [12] have all been the subject of recent investigation.  Mesothelioma, however, 
presents a unique challenge for image-based tumor volumetrics; before mesothelioma tumor 
volume can be adopted for clinical application, it is essential to understand the correlation 
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between tumor volume derived from images and the actual, physical tumor bulk that the images 
represent.  Although physical tumor weight and volume have been shown to relate to patient 
survival [13], the reliability of extrapolating physical tumor volume from imaging has been 
questioned in previous studies [14].  Ongoing work in this regard continues to demonstrate only 
moderate correlation between image-based mesothelioma tumor volume and both the physical 
weight of the resected tumor and the pathologic T stage. 
 Objective radiologic response rate is the key efficacy endpoint in early development of 
new therapies.  In phase II trials, response rate is often the primary study endpoint, and even in 
randomised phase III studies, response rate may be used as a correlative measure of efficacy.  
The morphology and growth characteristics of mesothelioma, however, differ from many other 
solid tumors in that the disease often forms a rind around the pleural cavity, with a sheet-like 
rather than spherical growth pattern.  The RECIST (Response Evaluation Criteria in Solid 
Tumors) guidelines [15] used unidimensional measurements, which were ostensibly better suited 
for measurement of mesothelioma rind thickness; however, RECIST required measurement of a 
tumor’s longest diameter, and the underlying assumption was of a spherical growth pattern.  The 
poor suitability of RECIST for measurement of mesothelioma and discrepancies between patient 
response based on RECIST and the earlier World Health Organization (WHO) guidelines [16] 
were soon revealed [17-18].  Modified RECIST for mesothelioma [19] was developed to address 
this deficiency.  Discrepancies in the practical implementation of modified RECIST, however, 
have led to confusion and inconsistent approaches to tumor measurement and response 
assessment.  This concern, along with the update to RECIST that was provided by RECIST 1.1 
[20], indicate that a revision to modified RECIST is needed. 
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2. Imaging with indocyanine green for intraoperative detection of residual disease 
 A subset of patients with epithelioid malignant mesothelioma limited to the hemithorax 
may benefit from an approach that includes surgery involving extrapleural pneumonectomy or a 
lung-preserving operation such as pleurectomy/decortication [21].  Regardless of the approach, 
the goal of surgery is macroscopic complete resection.  Despite aggressive multimodality therapy 
for “resectable” mesothelioma, prognosis remains poor, potentially in part due to residual 
disease.  At the conclusion of surgery, it can be challenging to discriminate residual disease from 
scar and normal tissue [22].  Keating and colleagues used near-infrared (NIR) molecular imaging 
using indocyanine green (ICG) for the intraoperative localization of tumors, lymph nodes, and 
metastases [23-25] and, more specifically, for the evaluation of margins following mediastinal 
tumor resection [26].  ICG is a non-targeted, near-infrared optical contrast agent that localizes to 
tumors through the enhanced permeability and retention effect.  This group investigated NIR 
intraoperative molecular imaging with ICG for the detection of mesothelioma tumor deposits to 
assess for resection completeness. 
 Eight patients with biopsy-proven epithelial malignant pleural mesothelioma were 
enrolled in a pilot clinical trial.  All patients underwent 5 mg/kg of intravenous ICG injection 24 
hours prior to surgery.  The following day, a NIR imaging device was used to detect tumor 
fluorescence intraoperatively.  After what was believed to be complete tumor excision, the 
wound bed was reimaged for residual fluorescence indicative of retained tumor.  When residual 
fluorescence was detected, additional tissue was resected, if feasible.  Specimens were sent for 
pathologic correlation. 
 All patients underwent ICG injection with no evidence of drug toxicity.  Intraoperative 
NIR fluorescence localized to mesothelioma in all cases.  Following tumor excision, 
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fluorescence was confirmed ex vivo (Figure 1).  The mean in vivo NIR tumor-to-background 
ratio was 3.2 (IQR 2.9-3.4).  After what was thought to be complete tumor excision, residual 
disease was discovered upon wound-bed imaging in all eight patients.  The number of additional 
resected specimens following wound-bed imaging ranged from one to four (mean 1.8).  Disease 
was typically discovered in difficult-to-reach places, including the costophrenic sulcus and 
directly beneath or adjacent to the thoracotomy incision.  The mean NIR tumor-to-background 
ratio of the resected residual tumor deposits was 2.8 (IQR 2.6-3.1); these resected specimens 
ranged in size from 0.3 mm to 2.2 cm (mean 0.9 cm).  In all cases, the additionally resected 
fluorescent tissue was confirmed as malignant mesothelioma on pathology. 
 In conclusion, NIR intraoperative molecular imaging using ICG localizes to malignant 
pleural mesothelioma and aids in detection of residual disease for improved resection.  A larger 
clinical trial is needed to investigate the impact of NIR intraoperative imaging on patient 
survival. 
3. Utility of delayed phase enhancement MRI 
 Although modern cross-sectional imaging has high spatial resolution, limitations in tissue 
contrast remain a challenge for staging of malignant pleural mesothelioma.  This limitation is a 
particular challenge on CT, where mesothelioma has a similar tissue attenuation to adjacent 
structures including chest wall musculature, diaphragm and pericardium, and complex pleural 
effusions [27,28].  Unfortunately, on conventional imaging protocols, mesothelioma often does 
not enhance sufficiently to allow for consistent, accurate pre-operative staging.  Since MRI has 
superior tissue contrast, MRI is sometimes employed to further characterize mesothelioma cases 
suspicious for local invasion on CT [27].  Although MRI does have superior tissue contrast, 
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subtle local invasion can still be a challenge to detect with imaging.  Limitations in imaging are 
partially responsible for the significant upstaging of disease that occurs in patients with 
mesothelioma who undergo pleurectomy; in a study by Rusch et al., for example, as many as 
80% of patients with stage 1 and 2 disease and 23% of patients with stage 3 disease were 
upstaged post-operatively [21]. 
 To determine whether tumor enhancement is optimal at the conventional imaging phase 
post intravenous contrast injection, Katz and colleagues conducted a retrospective study of 
patients with mesothelioma undergoing MRI for pre-operative staging.  Since these examinations 
included pre-contrast imaging and multiple acquisitions following injection of intravenous 
gadolinium, a time-enhancement curve for each patient could be constructed.  MRI exams for a 
total of 10 patients were analyzed; each scan demonstrated tumor with a thickness measurement 
of at least 5 mm, and all analyzed series had been acquired with fixed image-acquisition 
parameters.  Regions of interest were obtained from each phase of enhancement, and time-
enhancement curves were generated using maximal signal intensities (normalized to background) 
at each time delay.  These analyses revealed that the mesothelioma tumor enhancement at the 
conventional phase delay (40-60 sec) did not represent the maximal possible tumor 
enhancement, which occurred at a later time point for all 10 patients (Figure 2). 
 To estimate an optimal time delay for mesothelioma enhancement, the MRI enhancement 
data from these patients were employed to create best-fit models, which then were used to 
determine predicted maximum values.  Based on this technique, the peak tumor enhancement 
was estimated to occur at 280 sec following IV contrast administration.  At a time delay of 280 
sec, 70% and 60% of patients are projected to have reached >85% and >90%, respectively, of the 
peak projected signal intensity. 
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 These data strongly suggest that the optimal mesothelioma contrast enhancement on MRI 
occurs at a time delay longer than is typically employed in routine clinical imaging.  This finding 
is important since improved tumor enhancement may allow for increased accuracy in staging and 
therapy response assessment through improved tissue contrast.  Since the kinetics of intravenous 
contrast administration on CT is similar to MRI, it is highly likely that conventional CT chest 
imaging also could achieve improved tumor enhancement at a greater time delay than typically 
employed (40-60 sec).  The impact of delayed phase enhancement on radiologic mesothelioma 
staging accuracy and therapy response assessment warrants further study, since accurate staging 
is critical to providing patients with the best opportunity for treatment success. 
4. Optimization of early contrast-enhancement MRI 
 Radiologic detection of pleural malignancy is difficult, because pleural thickening may 
be minimal or absent, particularly in early-stage malignant pleural mesothelioma.  Moreover, 
pleural tumours are frequently distributed heterogeneously over a large area and interspersed 
with regions of benign or normal pleura.  These challenges are reflected in routine diagnostic CT 
scans, with two recent studies reporting CT sensitivities for pleural malignancy of 68% and 57% 
[29-30].  In a pilot study, Tsim and colleagues sought to develop a novel perfusion-based MRI 
biomarker for pleural malignancy that utilises the high spatial resolution provided by MRI; this 
technique was intended to target typical early features of the pleural tumour micro-environment, 
including neovascularisation and increases in constituent blood vessel density [31-32]. 
 Twenty-four patients with suspected mesothelioma prospectively underwent contrast-
enhanced CT, MRI, and subsequent diagnostic thoracoscopy.  The MRI protocol was developed 
with the first six patients; the subsequent 18 patients had complete contrast-enhanced MRI scans, 
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which consisted of T1-weighted, 3D-spoiled-gradient-echo sequences acquired at baseline, 40 
seconds, 80 seconds, and 4.5, 9, and 13.5 minutes after contrast injection.  The mean signal 
intensity of representative parietal pleura was measured in 15 regions of interest (ROIs) (Figure 
3(a) and (b)).  Early contrast enhancement (ECE) was defined objectively by an early (≤4.5 
minutes) peak in mean signal intensity.  Patient images were classified as malignant if at least 
one ROI demonstrated ECE (Figure 3(c) and (d)).  Signal intensity gradient was calculated (1) 
within individual ROIs and (2) per patient as the mean across all ROIs.  Diagnostic performance 
and inter-observer agreement for ECE were evaluated.  Mean signal intensity gradient for each 
patient was correlated with microvessel density measured in paraffin-embedded thoracoscopic 
pleural biopsies from representative anatomic regions and stained with CD34 and Factor VIII.  
To assess the contribution of interspersed benign disease to the diagnostic performance of ECE, 
receiver operating characteristic (ROC) curves were plotted based on the signal intensity gradient 
within all ROIs and then based on the signal intensity gradient only from ROIs demonstrating 
ECE in patients with pleural malignancy versus benign disease (Figure 3 (e) and (f)). 
 Eighteen of the 24 patients (mean age 73+8 years) had a history of asbestos exposure, and 
twelve of these patients had maximum pleural thickening ≤10mm.  The diagnostic performance 
and reproducibility of ECE were as follows: sensitivity 91%, specificity 86%, positive predictive 
value 91%, negative predictive value 85%, and inter-observer agreement 0.766.  A moderate 
correlation was obtained between mean signal intensity gradient and microvessel density 
measured using both CD34 and Factor VIII (r=0.63, p=0.044 and r=0.72, p=0.016, respectively). 
 It is interesting to note the concordance in peak contrast-enhancement time points 
reported in this study and the study by Katz in the previous section.  65% (66/101) of the 
malignant ROIs defined in this study peaked at 4.5 minutes, consistent with the 280-second peak 
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reported independently by Katz.  Future studies will allow greater understanding of how these 
observations relate to each other and how they can best applied.  This work will also hopefully 
lead to common terminology, since the use of “early contrast enhancement” and “delayed phase 
enhancement” for potentially similar contrast behaviour is likely to lead to confusion. 
 In this pilot study ECE appeared to be an accurate and reproducible, perfusion-based 
biomarker of pleural malignancy.  A larger study is required to reliably define the performance 
of ECE relative to existing approaches, including CT- and MRI-based tumor morphology.  
Excluding ECE-negative ROIs improved the discriminant performance of the ROI-based signal-
intensity gradient, probably because these areas represent interspersed benign pleural disease in 
patients with low-volume pleural malignancy (confirmed thoracoscopically in this study).  ECE 
assessment can be performed in patients with minimal pleural thickening, suggesting a potential 
role in the detection of early-stage mesothelioma or low-volume metastatic pleural metastases. 
5. Histogram analysis of DW-MRI during early chemotherapy to predict outcome 
 Patients with unresectable malignant pleural mesothelioma are most commonly treated 
with palliative chemotherapy, while treatment efficacy is radiologically monitored using 
modified RECIST to evaluate change in tumor thickness.  Anatomy-based assessments of 
response have limitations, however, which is one reason why prediction of survival is often 
difficult [33].  Even multiparametric MR imaging parameters can be insufficient for 
differentiating long- and short-term surviving patients, probably due to the large heterogeneity of 
disease phenotypes, which strongly influences response to therapy and disease appearance on 
imaging.  In this study Coolen and colleagues examined the value of diffusion-weighted MR 
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imaging (DWI) using tumor volume and four first-order histogram-based parameters (mean, 
standard deviation, skewness, and kurtosis) to assess treatment outcome. 
 Fifteen consecutive patients with inoperable mesothelioma undergoing systemic 
palliative chemotherapy (cisplatin-pemetrexed) were included in the study.  Anatomic and 
functional sequences (including DWI acquired using different diffusion sensitivities with six b-
values up to 1000 mm2/s, from which the apparent diffusion coefficient maps can be calculated 
[34]) were performed on a 3T MRI scanner according to a previously established protocol [35] at 
baseline and again after one month, just before the second chemotherapy session.  Histograms of 
apparent diffusion coefficient (ADC) values were constructed for each patient based on the 
ADCavg (calculated from all six b-values) of each pixel within the tumor and the ADClow 
(calculated from the first three b-values: 0, 50, and 100 mm2/s) of each pixel within the tumor.  
Differences in volume and the first-order histogram parameters between patients with long-term 
and short-term progression-free survival (PFS, cut-off: 170 days) and overall survival (OS, cut-
off: 440 days) were calculated, and Mann-Whitney U tests were used to evaluate statistical 
significance. 
 When using baseline scan parameters to differentiate between patients with long- and 
short-term OS, the kurtosis of the ADClow histogram and the skewness of the ADClow histogram 
were significantly different (p=0.004 and 0.006, respectively) with thresholds of 8.25 and 2.25, 
respectively (higher values indicated shorter OS).  Also, higher baseline tumor volumes were 
indicative of shorter OS (p=0.009, threshold 772 ml).  Figure 4 illustrates a case for which the 
parameters predict a good prognosis despite inoperable stage IV disease. 
 Similar findings were observed at the follow-up time point, for which the mean, kurtosis, 
and skewness of the ADClow histogram were significantly different between long- and short-term 
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OS patients (p-values 0.004, 0.02, and 0.014, respectively).  Lower ADClow mean (threshold: 
3.25 x10-  mm2/s) and higher ADClow kurtosis (threshold: 10) and skewness (threshold: 2.3) were 
indicative of shorter OS.  Higher follow-up tumor volumes were indicative of shorter OS 
(p=0.009, threshold 386 ml).  These results were improved relative to tumor ADC values alone 
[3].  As expected, the results for differentiating between long- and short-term PFS were less 
encouraging, with only kurtosis of the baseline ADCavg histogram and mean of the follow-up 
ADClow histogram nearing significance (p=0.054 and 0.07, respectively); lower values of both 
parameters were predictive of shorter PFS. 
 First-order histogram analysis of ADC parameters during early palliative chemotherapy 
of inoperable mesothelioma patients can differentiate between patients with long- and short-term 
OS, although PFS separation is less accurate.  Histogram analysis demonstrates tumor 
heterogeneity and is the foundation for DWI as a biomarker [36-37].  Moreover, these findings 
suggest that DWI could be a useful tool for personalized care in mesothelioma patients; when a 
second-line option becomes clinically available (currently a highly unmet need), this type of 
therapy response evaluation will become especially crucial.  These preliminary data, however, 
require confirmation in a larger patient cohort, preferably with multicenter participation. 
6. Dynamic contrast-enhanced CT to assess tumor response 
 Clinical assessment of tumor response to treatment in malignant pleural mesothelioma 
patients currently relies on linear measurements of tumor thickness obtained according to the 
modified RECIST protocol [19].  Hemodynamic parameters derived from dynamic contrast-
enhanced computed tomography (DCE-CT) scans have been shown to be representative of  
physiologic changes in tumor tissue not necessarily reflected by changes in tumor thickness [38].  
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Few investigations have been made into the use of such hemodynamic parameters for the 
assessment of tumor response in mesothelioma patients.  A study by Gudmundsson and 
colleagues evaluated the utility of DCE-CT in the assessment of mesothelioma tumor response. 
 The standard CT imaging protocol for mesothelioma was modified to include a DCE-CT 
component, during which a 55-mm axial extent of thoracic anatomy demonstrating notable 
tumor burden was imaged at specific time points following the injection of contrast media.  The 
DCE-CT image-acquisition protocol included two dynamic phases, one during the first minute 
following contrast injection and another starting at approximately 115 seconds after the initial 
injection of contrast, following the acquisition of a standard CT scan of the full chest.  The 
patient cohort consisted of 16 non-consecutive mesothelioma patients, of whom eight were on 
treatment (including Vorinostat, Pemetrexed, cisplatin or carboplatin/Pemetrexed, 
cisplatin/Pemetrexed/CBP501, and GDC-0980) and eight were on observation.  After providing 
written informed consent, each patient underwent two clinically indicated CT scans, separated by 
approximately two months, that were augmented with the DCE-CT scan components. 
 To capture tumor burden in each standard CT scan, modified RECIST measurements [19] 
were obtained manually by a research radiologist, and CT-based tumor volume measurements 
were obtained using a semi-automated in-house method [7].  To define a region of interest for 
the computation of hemodynamic parameters, visible tumor (which might comprise more than 
one focus of disease) was manually contoured on the images from a single time point of the 
dynamic phases of each scan; these contours were automatically propagated across all time 
points within the scan using a deformable image registration technique [39].  The hemodynamic 
parameters of perfusion, peak CT value enhancement, blood volume, and time to peak 
enhancement [40-41] were calculated from the average of the contrast uptake curves obtained 
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from individual pixels within the tumor regions.  Changes in these parameters were calculated 
between the two DCE-CT scans acquired from each patient, and the means of the change in 
individual parameters were compared between the on-treatment and on-observation cohorts. 
 Although changes in hemodynamic parameters were not significantly different between 
the two patient cohorts for any of the measured parameters, patients on treatment demonstrated a 
mean relative decrease in blood volume and perfusion (-14.2% and -17.2%, respectively) 
compared with a mean relative increase in these parameters (+8.8% and +27.0%, respectively) 
for patients on observation.  Figure 5 shows the blood-volume map from an on-therapy 
mesothelioma patient that exhibits a mean decrease in blood volume of 25.6% between the two 
scans following two cycles of chemotherapy, whereas summed tumor thickness as measured by 
modified RECIST for this patient showed an increase of 12.8% between scans.  No statistically 
significant correlation was found across all patients between relative changes in hemodynamic 
parameters and changes in tumor size, either by modified RECIST or tumor volume. 
 Observed differences in hemodynamic parameter changes between patients on treatment 
and patients on observation suggest that DCE-CT could be a useful imaging modality for the 
assessment of pharmacodynamic endpoints in mesothelioma.  The clinical relevance of these 
trends should be investigated through future studies with larger numbers of patients and focused 
therapeutic regimens. 
7. Correlation of CT-based tumor volume and resected tumor weight 
 Tumor volume has been reported to be a valuable prognosticator for survival in patients 
with malignant pleural mesothelioma [6-7, 11, 42].  Opitz and colleagues sought to assess the 
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precision of preoperative CT-based tumor volume in terms of correlation with the actual weight 
of tumor resected during macroscopic complete resection. 
 Between October 2012 and March 2016 the weight of resected tumor specimens was 
measured in 28 patients undergoing (extended) pleurectomy/decortication ((e)P/D).  Median 
patient age at the time of surgery was 66 years (range 41–77 years).  Eighteen patients (64%) had 
right-sided mesothelioma , and mesothelioma showed an epithelioid histology in 26 patients 
(93%).  Three patients (11%) showed pathologic T (pT) stage 1, 8 (28%) patients were pT stage 
2, 14 (50%) patients were pT stage 3, and 3 (11%) patients were pT stage 4.  Median time 
between the pre-operative CT scan and surgery was 17 days (range 1-48 days). 
 Tumor volume in the pre-operative contrast-enhanced CT scan (n=19) or non-contrast-
enhanced CT component of the PET-CT scan (n=9) of all 28 patients was measured by an 
experienced radiologist using a commercially available semi-automated method as described 
previously [10].  On the CT component of the PET-CT scan, the initially semi-automated 
segmented tumor volume was modified manually in correlation with the PET images, which 
were scrolled simultaneously in a separate window; included in the tumor volume was soft tissue 
that corresponded with regions of fluorodeoxyglucose (FDG) activity and soft tissue that did not 
show FDG activity but that could be identified clearly as mesothelioma because of its nodular 
morphology.  Physical tumor volume was measured through a water-displacement method; the 
resected tumor specimen was submerged in a 1-liter graduated cylinder filled with 500 ml of 
physiologic salt solution, and the resulting increase in volume was recorded as tumor volume.  
Relations between tumor weight, tumor volume at surgery, CT-volume, cT stage and pT stage 
were analyzed using Spearman rank correlation. 
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 The median tumor volume assessed by CT was 53 ml (range 2-709 ml), and the median 
post-surgical tumor weight was 398 g (range 95-783 g).  The analysis revealed a moderate 
correlation between CT-based tumor volume and tumor weight (correlation coefficient 0.47, 
p=0.01) (Figure 6).  CT tumor volume and physical post-surgical tumor volume demonstrated 
moderate correlation (correlation coefficient 0.55, p=0.02), consistent with other studies [14].  
No significant correlation was observed between clinical T (cT) stage and tumor weight 
(correlation coefficient 0.31, p=0.1).  There was a weak correlation of CT tumor volume with pT 
stage (correlation coefficient 0.38, p=0.04) and a moderate correlation of tumor weight with pT 
stage (correlation coefficient 0.51, p=0.006). 
 The correlation between preoperatively assessed CT-based tumor volume and actual 
resected tumor weight was only moderate, but weight included more structures than tumor alone, 
such as pericardium and diaphragm.  The physical volume of the resected tumor specimen also 
was moderately correlated with the CT-measured volume.  Correlation between CT tumor 
volume and pT stage was only moderate; however, CT tumor volume is a better parameter for 
prediction of actual tumor weight in comparison to cT (both assessed by experienced 
radiologist).  The independent effect of the different variables on overall survival could not be 
assessed in the present analyses and will be further investigated. 
8. Towards modified RECIST 1.1 
 Modified RECIST [19] substantively altered the manner in which unidimensional 
measurements were acquired from the CT scans of malignant pleural mesothelioma patients.  
The measurement of longest tumor diameter specified by RECIST [15] was replaced, in 
modified RECIST, by tumor thickness measurements, and the up-to-ten target lesions of 
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RECIST was replaced by six measurement sites within the tumor.  Notably, while altering the 
vector in which the tumor was measured, modified RECIST did not attempt to alter the RECIST 
criteria for measurability or response.  Despite the underlying assumption that all other aspects of 
RECIST were to remain unaltered by the application of modified RECIST to mesothelioma, 
misinterpretations have evolved in its clinical implementation.  Furthermore, modified RECIST 
was conceived of and published as research to validate this new measurement paradigm and 
solve a key problem in the mesothelioma clinical research community; it was not intended to 
comprehensively describe a set of response criteria suitable for clinical trial implementation.  
The authors specifically noted that “further evaluation of these modified criteria should be 
performed before they can be incorporated routinely into future clinical trials” [19]; nevertheless, 
modified RECIST almost immediately became the standard for mesothelioma tumor response 
assessment. 
 Since modified RECIST was published, a number of gaps in application have become 
apparent, the relevance of some aspects of RECIST to mesothelioma has been questioned, and 
unaddressed issues have been identified (Figure 7).  Subsequent reports have sought to define the 
logistics of practical implementation of modified RECIST [43] or record inter-observer 
variability [44-45], but misinterpretations remain.  Furthermore, RECIST 1.1 [20] updated 
several aspects of RECIST in 2009, and an analogous, logically consistent revision of modified 
RECIST (“modified RECIST 1.1”) is warranted. 
 Modified RECIST 1.1 guidelines will need to address several important issues: (1) the 
definition of “minimum measurable disease” in mesothelioma, (2) the relevance of “target 
lesion” for a spatially distributed tumor such as mesothelioma, (3) the selection of measurement 
sites, (4) the role of non-pleural disease, (5) the impact of non-measurable pleural disease, and 
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(6) the definition of progressive disease.  The response classification criteria (the actual numeric 
values) that separate “partial response” from “stable disease” from “progressive disease” in 
mesothelioma are under investigation [46-47] but would require clinical trial validation prior to 
the recommendation of any alteration to the now-standard 30% decrease and 20% increase 
specified by RECIST; therefore, modified RECIST 1.1 will not address tumor response criteria. 
 A recent study [48] reported a clinically acceptable level of mesothelioma tumor 
thickness measurement variability for thicknesses in the range 5.0-7.5 mm; thus, modified 
RECIST 1.1 will likely recommend a reduction in the current 10-mm definition of minimum 
measurable disease.  The concept of “target lesion” is integral to RECIST; this concept, however, 
lacks relevance in mesothelioma with its spatially extensive presentation.  Modified RECIST 1.1, 
therefore, will formalize the substitution of “measurement site” for “target lesion” and will 
define a logical approach to the selection of up to six pleural measurement sites that meet the 
minimum measurable disease threshold (with an appropriate accommodation for bilateral 
disease).  Modified RECIST 1.1 will allow for the inclusion of longest diameter measurements 
from a specified number of non-pleural lesions to supplement the pleural tumor measurements.  
A set of descriptive labels for non-measurable pleural disease will be identified in modified 
RECIST 1.1, and the role of non-measurable disease in the classification of progressive disease 
will be outlined.  Furthermore, the meaning of a “new lesion” in the context of progressive 
disease in mesothelioma will be explored. 
 This session at the IMIG meeting provided a forum for discussion of response for 
malignant pleural mesothelioma, with the goal of moving towards harmonization of criteria for 
mesothelioma with the current RECIST 1.1.  Forthcoming modified RECIST 1.1 guidelines are 
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expected to resolve discrepancies and alleviate confusion that has developed with regard to 
image-based mesothelioma tumor response assessment. 
9. Conclusion 
 The 2016 International Conference of iMig highlighted a number of important imaging 
studies in malignant pleural mesothelioma.  Intraoperative optical imaging of mesothelioma has 
the potential to become an important tool for surgeons seeking to achieve a macroscopic 
complete resection.  The utility of MRI in mesothelioma continues to attract attention, from 
investigations of more advantageous contrast timing delays to the possible role of early contrast 
enhancement characteristics of pleural abnormalities in the detection of malignant tumors to the 
use of image features for patient survival stratification.  Beyond MRI, contrast-enhancement in 
CT is being investigated to evaluate tumor hemodynamics as a potential indicator of tumor 
response separate from size-based metrics.  Although tumor size derived from CT scans is 
expected to remain an important factor in patient management (with increased reliance on tumor 
volume), investigation continues to reveal only moderate correlation between CT-based tumor 
volume and physical tumor weight and volume.  The 2016 iMig conference recognized the 
important role of imaging in the assessment of tumor response in clinical trials by entitling the 
imaging session “Imaging and Endpoint Evaluation;” this session thus provided an appropriate 
forum for discussion of the issues that motivate the newly announced effort to craft “modified 
RECIST 1.1” for mesothelioma.  The biennial International Conference of iMig continues to 
provide an important opportunity to highlight imaging advances in the mesothelioma setting.  
The topics presented at the 2016 meeting are the focus of continued research effort and clinical 
investigation; further advances in these and other promising aspects of imaging are expected to 
be presented at iMig 2018 in Ottawa, Ontario, Canada. 
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(b) (c) 
FIGURE 1. (a) Pre-operative CT scan demonstrating focus of left-sided tumor.  
Resected tumor specimen imaged in (b) white light and (c) near infrared light (superimposed on 
the white-light image). 
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FIGURE 2. Delayed enhanced images demonstrate chest wall invasion. (a) Pre-contrast 
and (b) delayed contrast-enhanced fat-saturated T1-weighted images in a 54-year-old male with 
right-sided malignant pleural mesothelioma reveal robust differentiation of tumor (white arrow) 
from adjacent fluid with delayed phase enhancement. 
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FIGURE 3. (a) and (b) T1-weighted images acquired 4.5 minutes after contrast injection, with 
ROIs show in green.  (c) Signal intensity vs. time curve with 8 out of 15 ROIs demonstrating 
ECE (classified as malignant).  (d) Signal intensity vs. time curve with no ROIs demonstrating 
ECE (classified as benign).  (e) ROC curve based on signal-intensity gradient from all ROIs 
regardless of the presence or absence of ECE.  (f) ROC curve based on signal-intensity gradient 
from ECE-positive ROIs only, demonstrating superior discriminatory performance. 
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FIGURE 4.  45-year-old male with mesothelioma in the right hemithorax and chest wall and 
diaphragmatic invasion (OS: 650 days) scanned before and during systemic palliative 
chemotherapy.  Post-contrast 3D T1-weighted and DWI images at baseline (top row) and 1 
month before the second cycle of chemotherapy (bottom row) are shown along with 3D DWI 
volumetric data and fused b0/1000-ADC data on the left.  The follow-up scan histogram (dotted 
line) has a more acute peak (higher kurtosis) with a slight shift to the left (more positive 
skewness). 
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FIGURE 5.  Blood volume parameter maps of a patient before (left) and after (right) two 
cycles of chemotherapy.  Mesothelioma tumor contours (dashed lines) are indicated with arrows.  
The image values are unitless.  The mean value of the blood volume parameter for the tumors 
shown was 0.072 in the first scan and 0.054 in the second scan (a relative decrease of 25.6% 
between scans), whereas modified-RECIST-based tumor thickness measurements increased by 
12.8%. 
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FIGURE 6.  CT-based tumor volume plotted as a function of post-surgical tumor weight. 
Spearman rank correlation coefficient 0.47, p=0.01. 
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FIGURE 7.  Keys gaps in application, unaddressed or misinterpreted issues, and logistical 
concerns in the practical implementation of modified RECIST that have become apparent since 
its publication. 
Modified RECIST Gaps in Application 
 
1. Definition of minimum measurable disease was not stated (intended 
concordance with RECIST 1.0) 
2. Not explicit about the need to permanently record an image of the site 
and vector of measurement. 
3. Not explicit about the incorporation of measurement of lymph-
adenopathy into response assessment. 
4. Did not address the potential for early reporting of progression where 
response had reduced pleural thickening to a non-measurable level 
5. Did not provide guidance for measurement and response in the setting 
of non-pleural lesions but no measurable pleural disease 
6. Did not provide guidance on measurement of fissural pleural thickening 
7. Did not provide guidance on measurement of bilateral pleural disease 
